Abeona Therapeutics Provides Regulatory Update on Pz-cel
April 22, 2024 16:05 ET
|
Abeona Therapeutics Inc.
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024 08:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
March 18, 2024 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024 16:05 ET
|
Abeona Therapeutics Inc.
CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
February 01, 2024 07:30 ET
|
Abeona Therapeutics Inc.
- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the...
Abeona Therapeutics Announces $50 Million Credit Facility
January 08, 2024 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2023 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
November 27, 2023 07:30 ET
|
Abeona Therapeutics Inc.
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc....
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
November 13, 2023 07:30 ET
|
Abeona Therapeutics Inc.
Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly...